CA2726114A1 - Diazacarbazoles and methods of use - Google Patents
Diazacarbazoles and methods of use Download PDFInfo
- Publication number
- CA2726114A1 CA2726114A1 CA2726114A CA2726114A CA2726114A1 CA 2726114 A1 CA2726114 A1 CA 2726114A1 CA 2726114 A CA2726114 A CA 2726114A CA 2726114 A CA2726114 A CA 2726114A CA 2726114 A1 CA2726114 A1 CA 2726114A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- cr14r15
- groups
- heterocyclyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6075008P | 2008-06-11 | 2008-06-11 | |
| US61/060,750 | 2008-06-11 | ||
| US14800409P | 2009-01-28 | 2009-01-28 | |
| US61/148,004 | 2009-01-28 | ||
| PCT/US2009/003481 WO2009151589A1 (en) | 2008-06-11 | 2009-06-10 | Diazacarbazoles and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2726114A1 true CA2726114A1 (en) | 2009-12-17 |
Family
ID=41066268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2726114A Abandoned CA2726114A1 (en) | 2008-06-11 | 2009-06-10 | Diazacarbazoles and methods of use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110124654A1 (https=) |
| EP (1) | EP2324024B1 (https=) |
| JP (2) | JP5677945B2 (https=) |
| KR (2) | KR101764556B1 (https=) |
| CN (1) | CN102119162B (https=) |
| AU (1) | AU2009258115B2 (https=) |
| BR (1) | BRPI0909957A2 (https=) |
| CA (1) | CA2726114A1 (https=) |
| ES (1) | ES2392489T3 (https=) |
| IL (1) | IL209548A (https=) |
| MX (1) | MX2010013606A (https=) |
| WO (1) | WO2009151589A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0909957A2 (pt) * | 2008-06-11 | 2016-04-19 | Genentech Inc | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" |
| ES2621857T3 (es) | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| AR090789A1 (es) * | 2012-04-23 | 2014-12-10 | Genentech Inc | Intermediarios y procesos para la preparacion de compuestos |
| WO2014116859A1 (en) * | 2013-01-23 | 2014-07-31 | The University Of Chicago | Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| JP6194416B2 (ja) | 2013-10-08 | 2017-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | タウ−petリガンドとしてのジアザカルバゾール誘導体 |
| JP6840931B2 (ja) * | 2015-03-09 | 2021-03-10 | 東ソー株式会社 | 縮環芳香族化合物の製造方法 |
| US20170067946A1 (en) | 2015-06-08 | 2017-03-09 | Zac WHEELER | Monitoring system with low power usage |
| EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018046428A1 (en) | 2016-09-09 | 2018-03-15 | F. Hoffmann-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0300894A3 (en) * | 2000-03-15 | 2008-05-28 | Sanofi Aventis Deutschland | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use |
| WO2001068648A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CN1186324C (zh) * | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| BRPI0407544A (pt) * | 2003-02-17 | 2006-02-14 | Pharmacia Italia Spa | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2170886A1 (en) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| BRPI0909957A2 (pt) * | 2008-06-11 | 2016-04-19 | Genentech Inc | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" |
-
2009
- 2009-06-10 BR BRPI0909957A patent/BRPI0909957A2/pt not_active Application Discontinuation
- 2009-06-10 JP JP2011513493A patent/JP5677945B2/ja not_active Expired - Fee Related
- 2009-06-10 KR KR1020167015993A patent/KR101764556B1/ko not_active Expired - Fee Related
- 2009-06-10 AU AU2009258115A patent/AU2009258115B2/en not_active Ceased
- 2009-06-10 KR KR1020117000608A patent/KR20110015699A/ko not_active Withdrawn
- 2009-06-10 CN CN200980131217.3A patent/CN102119162B/zh not_active Expired - Fee Related
- 2009-06-10 ES ES09762885T patent/ES2392489T3/es active Active
- 2009-06-10 CA CA2726114A patent/CA2726114A1/en not_active Abandoned
- 2009-06-10 MX MX2010013606A patent/MX2010013606A/es active IP Right Grant
- 2009-06-10 EP EP09762885A patent/EP2324024B1/en active Active
- 2009-06-10 WO PCT/US2009/003481 patent/WO2009151589A1/en not_active Ceased
- 2009-06-10 US US12/997,069 patent/US20110124654A1/en not_active Abandoned
-
2010
- 2010-11-24 IL IL209548A patent/IL209548A/en not_active IP Right Cessation
-
2014
- 2014-05-19 JP JP2014103195A patent/JP2014196309A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009258115B2 (en) | 2015-01-29 |
| EP2324024B1 (en) | 2012-09-26 |
| KR20160074680A (ko) | 2016-06-28 |
| BRPI0909957A2 (pt) | 2016-04-19 |
| JP2011522888A (ja) | 2011-08-04 |
| JP5677945B2 (ja) | 2015-02-25 |
| KR101764556B1 (ko) | 2017-08-02 |
| JP2014196309A (ja) | 2014-10-16 |
| AU2009258115A2 (en) | 2011-05-12 |
| WO2009151589A1 (en) | 2009-12-17 |
| ES2392489T3 (es) | 2012-12-11 |
| CN102119162B (zh) | 2014-10-08 |
| EP2324024A1 (en) | 2011-05-25 |
| IL209548A0 (en) | 2011-01-31 |
| MX2010013606A (es) | 2010-12-21 |
| IL209548A (en) | 2014-03-31 |
| KR20110015699A (ko) | 2011-02-16 |
| AU2009258115A1 (en) | 2009-12-17 |
| US20110124654A1 (en) | 2011-05-26 |
| CN102119162A (zh) | 2011-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009258115B2 (en) | Diazacarbazoles and methods of use | |
| US8293763B2 (en) | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents | |
| US7923456B2 (en) | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | |
| US7893085B2 (en) | Aza-benzothiophenyl compounds and methods of use | |
| AU2009258124B2 (en) | Diazacarbazoles and methods of use | |
| EP2164850B1 (en) | N-substituted azaindoles and methods of use | |
| US20110130406A1 (en) | Pyrazolo-pyridines as tyrosine kinase inhibitors | |
| CA2782213A1 (en) | 1,7-diazacarbazoles and their use in the treatment of cancer | |
| US20150368244A1 (en) | Diazacarbazoles and methods of use | |
| EP2300457B1 (en) | Substituted pyrroles and methods of use | |
| HK40091719A (zh) | 取代的稠杂环化合物及其制备方法与应用 | |
| HK40091719B (zh) | 取代的稠杂环化合物及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140527 |
|
| FZDE | Discontinued |
Effective date: 20170109 |